{"id":"placebo-1-bag-three-times-a-day","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2134545","moleculeType":"Small molecule","molecularWeight":"427.51"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo 1 bag, three times a day","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:11:37.083672+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:11:42.953282+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo 1 bag, three times a day","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:11:43.463303+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2134545/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:11:44.703393+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a non-active substance administered in clinical trials to establish baseline outcomes and control for the placebo effect—the therapeutic benefit arising from patient expectation rather than the drug's inherent properties. It allows researchers to isolate the true efficacy of an investigational treatment by comparing outcomes between placebo and active drug groups.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control in clinical research.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:30.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:11:46.296437+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control arm (non-therapeutic use)"}]},"trialDetails":[{"nctId":"NCT03773900","phase":"NA","title":"Characterization of Gut Microbiota Composition and Activity After a Daily Supplementation of 4.5 g/Day of ChitinGlucan Fibre During 3 Weeks in At-cardiometabolic Risk Volunteers","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-11-07","conditions":"Cardiometabolic Risk, Abdominal Obesity","enrollment":19},{"nctId":"NCT06699420","phase":"PHASE4","title":"Qishenyiqi Dripping Pill for Coronary Microvascular Disease","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-11-08","conditions":"Coronary Microvascular Disease","enrollment":162},{"nctId":"NCT06699407","phase":"PHASE4","title":"Qishenyiqi for Ventricular Remodeling After Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-11-20","conditions":"Chronic Stable Heart Failure","enrollment":210},{"nctId":"NCT06175468","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of \"Formosa 1-Breath Free (NRICM101) \" in Subjects With the Symptoms of COVID-19 or Influenza-like Disease","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2023-12-15","conditions":"Influenza Viral Infections, COVID-19","enrollment":170},{"nctId":"NCT05845983","phase":"NA","title":"LA Improves the Prognosis of Patients With ICVD","status":"NOT_YET_RECRUITING","sponsor":"Huaqiu Zhang","startDate":"2023-05-04","conditions":"Ischemia, Cerebrovascular Ischemia, Cognitive Impairment","enrollment":236},{"nctId":"NCT05764668","phase":"PHASE3","title":"Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome)","status":"UNKNOWN","sponsor":"DoCare Pharmaceutial Technology Co.,Ltd","startDate":"2022-11-15","conditions":"Cough","enrollment":480},{"nctId":"NCT05333315","phase":"NA","title":"Clinical Trials of Five Different Food Supplements With Restriction Diet in Adults","status":"COMPLETED","sponsor":"University of Primorska","startDate":"2022-04-20","conditions":"Overweight and Obesity, Inflammation, Hypercholesterolemia","enrollment":120},{"nctId":"NCT05035979","phase":"PHASE3","title":"Oral Baidi Quzhi Granule Combined With Ju Ying Cream for Acne Vulgaris","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2021-12-01","conditions":"Acne Vulgaris","enrollment":472},{"nctId":"NCT04471298","phase":"PHASE1","title":"A Study of Qishenyiqi Dripping Pills in Healthy Participants","status":"COMPLETED","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2020-09-21","conditions":"Healthy Participants","enrollment":36},{"nctId":"NCT04530617","phase":"PHASE2","title":"Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients","status":"TERMINATED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2020-10-05","conditions":"Covid19, Diabetes, Hypertension","enrollment":246},{"nctId":"NCT04408261","phase":"PHASE2","title":"BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome","status":"UNKNOWN","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2020-07-22","conditions":"Stroke, Ischemic, Coronary Artery Disease, Angina Pectoris, Stable","enrollment":432},{"nctId":"NCT04270071","phase":"PHASE4","title":"Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2020-12","conditions":"Coronary Heart Disease, Stable Angina","enrollment":80},{"nctId":"NCT04340297","phase":"PHASE3","title":"Tongjiang Series Prescription Combined With PPIs Descending Ladder Withdrawal in Treating Nonerosive Reflux Disease","status":"UNKNOWN","sponsor":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","startDate":"2020-06-15","conditions":"Nonerosive Reflux Disease","enrollment":180},{"nctId":"NCT04435509","phase":"NA","title":"Management of Mild Cognitive Impairment Patients With Greek Mountain Tea - TEAMENTIA","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-17","conditions":"Mild Cognitive Impairment","enrollment":50},{"nctId":"NCT04028544","phase":"PHASE4","title":"The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2019-03-26","conditions":"Heart Failure","enrollment":5380},{"nctId":"NCT03787563","phase":"NA","title":"Herbal Tea in the Treatment of Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Composite Interceptive Med Science","startDate":"2019-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT02993419","phase":"PHASE4","title":"Bacillus Particles Prevent Children Antibiotics Associated Diarrhea","status":"UNKNOWN","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2016-12","conditions":"Antibiotic-associated Diarrhea","enrollment":480},{"nctId":"NCT01883440","phase":"PHASE2","title":"Glucose Oxidase as Treatment Against Common Cold","status":"COMPLETED","sponsor":"Krister Tano","startDate":"2013-01","conditions":"Common Cold","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2134545"},"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo 1 bag, three times a day","genericName":"Placebo 1 bag, three times a day","companyName":"Qilu Hospital of Shandong University","companyId":"qilu-hospital-of-shandong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces no pharmacological effect and serves as an inert control in clinical research. Used for Clinical trial control arm (non-therapeutic use).","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:11:46.296437+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}